Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib plus 131I-MIBG for relapsed or refractory high-risk neuroblastoma
ISRCTN64894508Phase 2Recruiting
- Sponsor
- University of Birmingham
- Start
- Dec 2024
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
01
Overview
Phase 2, open-label trial of talazoparib and Iobenguane I-131 in neuroblastoma, sponsored by University of Birmingham. Primary endpoints: Incidence of dose-limiting toxicities and Incidence of adverse events and serious adverse events. Started Dec 2024; status: recruiting.
02
Drugs
talazoparibIobenguane I-131
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on ISRCTN64894508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN64894508.